Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad280 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Trenton Bushmaker und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Montana. Hauptthemen laut MEDLINE: Ebolavirus, Hemorrhagic Fever, Ebola, Ebola Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, Division of Intramural Research.
Abstract (Originalsprache)
Vesicular stomatitis virus–Ebola virus (VSV-EBOV) vaccine has been successfully used in ring vaccination approaches during EBOV disease outbreaks demonstrating its general benefit in short-term prophylactic vaccination, but actual proof of its benefit in true postexposure prophylaxis (PEP) for humans is missing. Animal studies have indicated PEP efficacy when VSV-EBOV was used within hours of lethal EBOV challenge. Here, we used a lower EBOV challenge dose and a combined intravenous and intramuscular VSV-EBOV administration to improve PEP efficacy in the rhesus macaque model. VSV-EBOV treatment 1 hour after EBOV challenge resulted in delayed disease progression but little benefit in outcome. Thus, we could not confirm previous results indicating questionable benefit of VSV-EBOV for EBOV PEP in a nonhuman primate model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Montana.
- Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
- Médecins Sans Frontières, Brussels, Belgium.
- Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, Texas.
ORCID-Profile: Andrea Marzi, Heinz Feldmann
Förderung
- NHLBI NIH HHS
- NIH HHS
- Division of Intramural Research
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Bushmaker, T., Feldmann, F., Lovaglio, J., Saturday, G., Griffin, A. J., O'Donnell, K. L., Strong, J. E., Sprecher, A., Kobinger, G., Geisbert, T. W., Marzi, A., & Feldmann, H. (2023). Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad280
Vancouver
Bushmaker T, Feldmann F, Lovaglio J, Saturday G, Griffin AJ, O'Donnell KL, et al. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad280
BibTeX
@article{Bushmaker2023,
author = {Bushmaker, Trenton and Feldmann, Friederike and Lovaglio, Jamie and Saturday, Greg and Griffin, Amanda J and O'Donnell, Kyle L and Strong, James E and Sprecher, Armand and Kobinger, Gary and Geisbert, Thomas W and Marzi, Andrea and Feldmann, Heinz},
title = {Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad280}
}
EUVIMED